Processing...
Clinical Trials for Esophageal Cancer
Search
Search
There are 99 active trials for advanced/metastatic esophageal cancer.
Click on a trial to see more information.
99 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with previously treated, locally advanced unresectable or metastatic FAP-positive solid tumors receive intravenous LY4337713, an investigational lutetium-177 radioligand that targets fibroblast activation protein on cancer-associated fibroblasts to deliver radiation to tumors. Eligible cancers include pancreatic, breast, ovarian, gastric, colorectal, esophageal, and cholangiocarcinoma.
ClinicalTrials.gov ID: NCT07213791
TrialFetch AI summary: Adults with measurable advanced or metastatic solid tumors who have exhausted standard treatment options or have no standard therapy receive intravenous TJ101, a bispecific antibody-drug conjugate targeting EGFR and B7-H3, every 21 days. Prior topoisomerase I inhibitor treatment is excluded.
ClinicalTrials.gov ID: NCT07181473
TrialFetch AI summary: Adults with refractory, locally advanced or metastatic NSCLC, triple-negative breast cancer, head and neck squamous cell carcinoma, esophageal or gastric/GEJ cancer, or cervical, endometrial, or ovarian cancer (ECOG 0–1) receive NRM-823 alone or with an immune checkpoint inhibitor. NRM-823 is an investigational T-cell engager intended to bring T cells into contact with tumor cells; its tumor-binding target has not been publicly confirmed.
ClinicalTrials.gov ID: NCT07182149
TrialFetch AI summary: Adults with relapsed or refractory, locally advanced or metastatic solid tumors harboring a SMARCA4 loss-of-function mutation receive once-daily oral PLX-61639 after approved treatment options have been exhausted or deemed unsuitable. PLX-61639 is an investigational degrader that recruits DCAF16 to eliminate SMARCA2, a protein on which SMARCA4-deficient tumors may depend.
ClinicalTrials.gov ID: NCT07284186
TrialFetch AI summary: Adults with progressing relapsed or refractory, locally advanced inoperable or metastatic CRPC, colorectal, lung, head and neck, gynecologic, triple-negative breast, or esophageal squamous cell cancer receive 177Lu-BetaBart in a single-arm dose-escalation and expansion study. This investigational lutetium-177–labeled antibody targets B7-H3 (CD276) to deliver radiation to tumors.
ClinicalTrials.gov ID: NCT07189871
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors refractory to standard therapy or without proven effective options receive KIVU-107, an investigational PTK7-directed antibody-drug conjugate carrying an exatecan/topoisomerase I inhibitor payload. The study includes dose escalation followed by expansion at the recommended dose, with eligibility requiring measurable disease, ECOG 0–1, and adequate organ function.
ClinicalTrials.gov ID: NCT07229313
TrialFetch AI summary: Adults with ECOG 0–1 and measurable locally advanced/metastatic solid tumors co-expressing B7-H3 and PTK7, after progression/intolerance to prior therapy or lacking standard options, including NSCLC, ESCC, endometrial, ovarian, HNSCC, TNBC, colorectal, and CRPC. All participants receive IDE034, an investigational bispecific B7-H3/PTK7 antibody–drug conjugate with a topoisomerase I inhibitor payload, in dose-escalation and expansion cohorts.
ClinicalTrials.gov ID: NCT07503808
TrialFetch AI summary: Adults with metastatic or unresectable locally advanced NSCLC, esophageal squamous cell carcinoma, or cutaneous melanoma after standard therapy or 1–2 prior systemic regimens receive IV PF-08046033 in 21-day cycles. PF-08046033 is an investigational GPNMB-directed antibody-drug conjugate delivering auristatin S to GPNMB-expressing tumor cells, with dose escalation followed by tumor-specific expansion cohorts.
ClinicalTrials.gov ID: NCT07519655
TrialFetch AI summary: Patients with ECOG 0–2 and measurable, unresectable locally advanced or metastatic solid tumors, including colorectal cancer, NSCLC, breast cancer, and upper GI adenocarcinomas; expansion focuses on refractory colorectal cancer and NSCLC. All receive IV IM-1617, an antibody–drug conjugate targeting an undisclosed receptor tyrosine kinase and delivering the HC74 topoisomerase-I inhibitor payload.
ClinicalTrials.gov ID: NCT07578571
TrialFetch AI summary: Adults with unresectable recurrent, locally advanced, or metastatic solid tumors, including endometrial and ovarian cancers, receive DBC-664 monotherapy in dose-escalation or expansion cohorts. DBC-664 is an investigational biologic with an undisclosed molecular target and mechanism of action.
ClinicalTrials.gov ID: NCT07705035